Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Alzheimer disease

Treatments for AD: towards the right target at the right time

Nature Reviews Neurology volume 19, pages 581–582 (2023)Cite this article

Subjects

The treatment of Alzheimer disease has entered a new era, with a number of disease-modifying anti-amyloid-β therapies reaching the market in the past few years. Here we discuss the newest advances from phase III trials of solanezumab and donanemab.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Haeberlein, S. B. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J. Prev. Alzheimers Dis. 9, 197–210 (2022).

    Google Scholar 

  2. van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388, 9–21 (2023).

    Article  PubMed  Google Scholar 

  3. Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease. JAMA 330, 512–527 (2023).

    Article  CAS  PubMed  Google Scholar 

  4. Sperling, R. A. et al. Trial of solanezumab in preclinical Alzheimer’s disease. N. Engl. J. Med. https://doi.org/10.1056/nejmoa2305032 (2023).

    Article  PubMed  Google Scholar 

  5. Honig, L. S. et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N. Engl. J. Med. 378, 321–330 (2018).

    Article  CAS  PubMed  Google Scholar 

  6. Sperling, R. A. et al. Anti-amyloid treatment in asymptomatic Alzheimer’s disease (A4) and longitudinal evaluation of amyloid risk and neurodegeneration (LEARN) study longitudinal results. In Alzheimer’s Association International Conference, available online at https://a4study.org/study-results/ (2023).

  7. Donohue, M. C. et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. J. Am. Med. Assoc. 317, 2305–2316 (2017).

    Article  CAS  Google Scholar 

  8. Jutten, R. J. et al. Finding treatment effects in Alzheimer trials in the face of disease progression heterogeneity. Neurology 96, e2673–e2684 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Flier, W. M. van der, Vugt, M. E. de, Smets, E. M. A., Blom, M. & Teunissen, C. E. Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementia. Nat. Aging 3, 494–505 (2023).

    Article  PubMed  Google Scholar 

  10. Tijms, B. M. et al. Large-scale cerebrospinal fluid proteomic analysis in Alzheimer’s disease patients reveals five molecular subtypes with distinct genetic risk profiles. Preprint at medRxiv https://doi.org/10.1101/2023.05.10.23289793 (2023).

Download references

Author information

Authors and Affiliations

  1. Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

    Wiesje M. van der Flier & Betty M. Tijms

  2. Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands

    Wiesje M. van der Flier & Betty M. Tijms

  3. Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

    Wiesje M. van der Flier

Authors
  1. Wiesje M. van der Flier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Betty M. Tijms
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wiesje M. van der Flier.

Ethics declarations

Competing interests

Research programmes of W.M.v.d.F. have been funded by ZonMW, NWO, EU-JPND, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Eisai, Combinostics. W.M.v.d.F. holds the Pasman chair. W.M.v.d.F. is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). W.M.v.d.F. has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, NovoNordisk, European Brain Council. W.M.d.v.F. is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, and Eisai. W.M.v.d.F. participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. All funding is paid to her institution. W.M.v.d.F. is a member of the steering committee of PAVE, and Think Brain Health. W.M.v.d.F. was associate editor of Alzheimer’s Research & Therapy in 2020–2021. W.M.v.d.F. is an associate editor at Brain. B.M.T. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van der Flier, W.M., Tijms, B.M. Treatments for AD: towards the right target at the right time. Nat Rev Neurol 19, 581–582 (2023). https://doi.org/10.1038/s41582-023-00869-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-023-00869-0

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research